Drugs / AZD2693
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05919069 | Jun 2023 → Sep 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05107336 | Nov 2021 → Mar 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04483947 | Nov 2020 → Dec 2023 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04142424 | Oct 2019 → Nov 2021 | metabolic disease, metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05809934 | Mar 2023 → Jul 2025 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2693 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05107336 ↗ |
| Action | Inhibit | “AZD2693 potently reduced PNPLA3 expression in human hepatocytes and livers of mice.” PMID 39798707 ↗ Jan 2025 |
| Modality | Antisense oligonucleotide | “AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA.” PMID 39798707 ↗ Jan 2025 |
| Route | Subcutaneous | “following subcutaneous (SC) SAD administration of AZD2693” NCT04142424 ↗ |
| Target | PNPLA3 | “AZD2693 is a liver-targeted antisense oligonucleotide against PNPLA3 mRNA.” PMID 39798707 ↗ Jan 2025 |